Neogenomics

NeoGenomics will offer Trapelo's clinical decision support system to providers, payors, and labs to aid precision oncology across all healthcare settings.

NeoGenomics will use its gene fusion panels to identify patients with solid tumors and an NRG1 fusion who might qualify for Elevation's Phase II CRESTONE study. 

The firm reported revenues of $126.0 million for the three-month period ended Dec. 31, 2020, up from $106.9 million in the same period last year.

News items for the in vitro diagnostics industry for the week of Feb. 1, 2021.

The partnership will help customers make evidence-based decisions regarding trial designs, companion diagnostics, and drug repurposing.

Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay. 

The firm will use the proceeds for general corporate purposes and to possibly acquire or invest in complementary businesses and technology.

BTIG highlighted the firm's cancer test portfolio, as well as its growing position in the liquid biopsy and minimal residual disease testing space.

Clinical test volume and requisitions received each grew about 2 percent year over year, while the average revenue per test fell 3 percent.